V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) antibody

Details for Product No. ABIN659471
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms
B-Raf, braf1, rafb1, b-raf1, sierrabraf, BRAF, 9930012E13Rik, AA120551, AA387315, AA473386, B-raf, Braf-2, Braf2, C230098H17, C87398, D6Ertd631e, Braf, HYPT11, SME, Sm-E, B-RAF1, BRAF1, NS7, RAFB1, C- ... show more
B-Raf, braf1, rafb1, b-raf1, sierrabraf, BRAF, 9930012E13Rik, AA120551, AA387315, AA473386, B-raf, Braf-2, Braf2, C230098H17, C87398, D6Ertd631e, Braf, HYPT11, SME, Sm-E, B-RAF1, BRAF1, NS7, RAFB1, C-RMIL, RMIL show less
Reactivity
Human
(235), (23), (20), (6), (4), (1), (1), (1)
Host
Mouse
(168), (62), (5), (2)
Clonality
Monoclonal
Conjugate
Un-conjugated
(12), (12), (12), (9), (9), (9), (3), (3), (3), (3), (3), (3), (3), (3)
Application
Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)
(160), (122), (69), (50), (46), (30), (21), (10), (3), (2), (1), (1)
Pubmed 2 references available
Quantity 0.1 mg
Options
Shipping to United States (Change)
Availability Will be delivered in 2 to 3 Business Days
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN659471
357.50 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Purified recombinant fragment of human BRAF expressed in E. Coli.
Isotype IgG1
Specificity Purified recombinant fragment of human BRAF expressed in E. Coli.
Purification This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Alternative Name BRAF
Background Synonyms: Serine protease inhibitor J6, 47 kDa heat shock protein, Collagen-binding protein, Colligin, Serpin H1,Hsp47, Cbp1, Serpinh1
Molecular Weight 84437 DA
Gene ID 12406
NCBI Accession NP_004324
UniProt P15056
Research Area Phospho-specific antibodies, Cell Signaling, Cancer, Signaling, Chromatin, Cell Structure
Application Notes The suggested dilution is: Western Bloting: = 1:500 - 2000. Immunohistochemistry: = 1:200 - 1000. Immunofluorescence: = 1:200 - 1000.
Comment

Background: BRAF: v-raf murine sarcoma viral oncogene homolog B1, also known as BRAF1, RAFB1, B-RAF1, FLJ95109. Entrez Protein NP_004324. It is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439). B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK), it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers. The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi, primary cutaneous melanomas and colorectal cancers.

Restrictions For Research Use only
Buffer PBS with 0.09% (w/v) sodium azide.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C/-20 °C
Storage Comment Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
Expiry Date 6 months
Background publications Riesco-Eizaguirre, Gutiérrez-Martínez, García-Cabezas et al.: "The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane." in: Endocrine-related cancer, Vol. 13, Issue 1, pp. 257-69, 2006 (PubMed).

Di Nicolantonio, Martini, Molinari et al.: "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, Issue 35, pp. 5705-12, 2008 (PubMed).

Validation Images
Did you look for something else?
back to top